CVBT Will Present at the UBS Global Life Sciences Conference.HENDERSON, Nev. -- CardioVascular BioTherapeutics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CVBT CVBT Cardiovascular Biotherapeutics, Inc CVBT Central Virginia Battlefields Trust (Fredericksburg, VA Civil War history organization) ) announced today that Mr. Daniel C. Montano, Chairman of the Board, President, and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CardioVascular BioTherapeutics, Inc. (CVBT), has been invited to present CVBT's Story at the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference scheduled for Monday, September 26 - Thursday, September 29, 2005 at the Grand Hyatt New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of at Grand Central Terminal in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Mr. Montano commented, "I am very pleased with this opportunity to present our company at this very prestigious event." Mr. Montano's presentation will be at 1:30 PM ET on September 29, 2005. His presentation is available to the public live, and by replay through audio webcast. The webcast can be accessed at www.cvbt.com or on the UBS Investment Bank website (www.ibb.ubs.com) or through direct link (http://event.streamx.us/event/20050926). The replay of Mr. Montano's presentation will be available at those sites three hours after his presentation time, and will be available until October 29, 2005. CardioVascular BioTherapeutics, Inc. (stock symbol:CVBT) is a biopharmaceutical company focused on developing a new drug for the treatment of cardiovascular diseases where the growth of new blood vessels can improve the outcome for patients with these diseases. Its drug candidate, Cardio Vascu-Grow(TM), is designed to facilitate the growth of new blood vessels in the heart and other tissues with an impaired vascular system. This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding our future revenues, cash usage and our cash flow breakeven point are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Cardio Vascu-Grow(TM), market acceptance of CardioVascular BioTherapeutics, Inc. products by our customers, future revenues, future expenses, future margins, cash usage, and financial performance. For a more detailed discussion of these and associated risks, see the Company's most recent documents filed with the Securities and Exchange Commission. Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics, Inc. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion